<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition</h2>
    <div class="badge">2025-09-09T12:10:32+00:00</div>
    <ul>
      <li>Novartis will pay $48.00 per share in cash at closing, a 59% premium to Tourmaline’s September 8 closing price and 127% above its 60-day volume-weighted average.</li>
<li>The deal is expected to close in the fourth quarter of 2025.</li>
<li>If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.</li>
<li>In April, Novartis acquired Regulus Therapeutics for an initial payment of $7.00 per share in cash or $0.8 billion.</li>
<li>Other Deals In 2025 To Bolster Heart and Kidney Drug Portfolio Earlier in 2025, Novartis agreed to acquire Anthos Therapeutics Inc.</li>
<li>for an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.</li>
<li>(NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition\n• Novartis will pay $48.00 per share in cash at closing, a 59% premium to Tourmaline’s September 8 closing price and 127% above its 60-day volume-weighted average.\n• The deal is expected to close in the fourth quarter of 2025.\n• If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.\n• In April, Novartis acquired Regulus Therapeutics for an initial payment of $7.00 per share in cash or $0.8 billion.\n• Other Deals In 2025 To Bolster Heart and Kidney Drug Portfolio Earlier in 2025, Novartis agreed to acquire Anthos Therapeutics Inc.\n• for an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.\n• (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/novartis-expand-heart-drug-portfolio-121032541.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>